Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on BioLife Solutions (BLFS – Research Report) and keeping the price target at $30.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yi Chen has given his Buy rating due to a combination of factors including anticipated sequential revenue growth for BioLife Solutions in 2025. The company’s revenue is expected to grow quarter-over-quarter, with projections for the full year remaining steady at $97.5 million. This growth is supported by management’s guidance on Cell Processing and evo and Thaw revenues, which are expected to contribute significantly to the company’s financial performance.
Additionally, BioLife Solutions’ cash position is projected to improve moderately in the latter half of 2025, following the acquisition of PanTHERA CryoSolutions. This acquisition not only strengthens the company’s portfolio with innovative cryopreservation solutions but also indicates a strategic use of capital. The valuation analysis, which considers comparable companies in the biopharma tools and services sector, supports a price target of $30. Potential risks include lower-than-expected product growth and market fluctuations, but the overall outlook remains positive, justifying the Buy rating.
According to TipRanks, Chen is an analyst with an average return of -13.7% and a 31.22% success rate. Chen covers the Healthcare sector, focusing on stocks such as Opko Health, Vivani Medical, and Orchestra BioMed Holdings.
In another report released on May 13, Maxim Group also maintained a Buy rating on the stock with a $34.00 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue